Bioten바이오텐

Bioten, a small KONEX-listed food and health ingredient company, shows no recent financial data in the pack and its shares have fallen about 30% over the past year.

Bioten (Bio10) makes natural-ingredient composites such as curcuminoid complexes and sells 15 health functional foods and 26 feed supplements, with early export steps in China and trademark work in the US, Indonesia and Vietnam. The pack contains no annual or trailing financials, valuation multiples or dividend data beyond a 0% yield, so the current business scale cannot be measured from it. The share price was ₩2,700 on 2026-10-29, a market cap of about ₩9.7B.

What stands out

• The share price is ₩2,700, up 2.1% over three months but down 30.4% over one year, and well below its 52-week high of ₩4,775, though above the low of ₩2,000.
• No revenue, profit or balance sheet figures were provided, so the filed financials cannot be assessed; valuation ratios are also unavailable.
• Recent filings include a change of CEO on 2026-07-21, an IR event on 2026-06-30 and the annual report for December 2025 filed on 2026-03-23.
• No news headlines were available in the pack for the period.
• Foreign ownership is 0% and no investor flow data was reported over the last 20 days.

What to watch

• The CEO change in July 2026 and whether it signals any shift in strategy, which the filings do not explain.
• Progress of the export expansion and trademark approvals in the US, Indonesia and Vietnam, which are described but not quantified.
• Any future filings that disclose revenue, profit or dividends, since the current pack lacks them.